ConcertAI, a company focused on artificial intelligence solutions for cancer care and life sciences, has announced the launch of a new suite of software tools designed to help pharmaceutical and healthcare organizations make better use of data in clinical trials, research, and commercialization.
Called the Precision Suite, the collection includes several AI-powered applications built to assist teams working in areas such as clinical trial design, patient recruitment, and post-market analysis. The technology is powered by ConcertAI’s proprietary platform, CARAai, and integrates a variety of healthcare data types, including electronic medical records, genomic data, insurance claims, and social health factors.
The company says its tools are designed to speed up insights and decision-making processes that typically require extensive manual work and time. The Precision Suite includes four primary tools:
- Precision Explorer: Intended for use by health economics, epidemiology, and medical teams, this tool allows users to analyze patient outcomes and test hypotheses more quickly by leveraging AI-curated oncology data.
- Precision Trials: Aimed at improving clinical trial operations, this tool supports tasks like study design and patient recruitment. The platform is designed to minimize costly delays by predicting trial needs and streamlining site selection and enrollment.
- Precision GTM: This application focuses on the commercialization phase, helping pharmaceutical companies track physician behavior, treatment patterns, and the adoption of new therapies. The goal is to allow for more agile and data-informed marketing strategies.
- Precision360: Serving as the data backbone for the suite, this system continuously updates a unified dataset that incorporates recent clinical, genomic, and social health information.
Company executives say the tools reflect a shift toward enterprise-scale AI applications in healthcare. “We’ve moved from point solutions to enterprise SaaS capabilities,” said Jeff Elton, Ph.D., ConcertAI’s vice chairman. “The launch of Precision Suite is part of our broader strategy to deliver scalable AI solutions for life sciences and healthcare.”
Eron Kelly, CEO of ConcertAI, highlighted the platform’s ability to handle diverse data types in near real time, positioning the toolset as a way to reduce operational costs and shorten the path to market for new therapies.
The first two applications, Precision Explorer and Precision Trials, are expected to become available by June 30, 2025.